Discovering to make the difference 

Aurigene provides collaborative Drug Discovery Services for Lead Generation/ Lead Optimization. The Business Model involves collaborative Drug Discovery with partners, on a risk- and reward-sharing basis. Typical Aurigene projects involve starting with a partner's target protein and delivering an Optimized Lead, ready to go into clinical development.

Aurigene employs both Structure Based Drug Design (SBDD) and conventional Screening technologies for Drug Discovery. SBDD involves structural screening, computational chemistry aided ligand design, mining and screening of novel chemical entities, thus providing direction for Lead Discovery and Medicinal Chemistry. Early animal work involving ADME and Toxicity improves the probability of success. The approach helps in identifying the challenges at a very early stage and helps in setting a road map for the next steps in the process, thus shortening the overall project timelines and mitigating risks.

Aurigene is also identifying and building a portfolio of product opportunities focused on metabolic disorders, cardiovascular diseases, oncology and inflammatory diseases. Programs are chosen for significant unmet needs, and start with validated disease targets having well-defined roadmaps for clinical development. These are projects specifically designed for partnering with Pharma and Discovery Biotech companies.

Target focus includes Kinases, Proteases, Nuclear Hormone Receptors and G-Protein Coupled Receptors.

Using the strength of its technology and approach, Aurigene is able to provide novel solutions; generate and deliver IP through early stage discovery programs to partners through significant speed and cost-effective innovation, coupled with the ability to rapidly scale-up scientific capabilities.